CRISPR Therapeutics AG (CRSP) Capital Expenditures (2015 - 2026)
CRISPR Therapeutics AG (CRSP) reported Capital Expenditures of $504000.0 for Q1 2026, up 144.66% on a YoY basis from $206000.0 in Q1 2025, and down 2.51% sequentially from $517000.0 in Q4 2025.
CRISPR Therapeutics AG (CRSP) Capital Expenditures (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 12 years of Capital Expenditures data on file, last reported at $504000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 144.66% year-over-year to $504000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 435.73% YoY), and the FY2025 full-year result was $914000.0, up 493.51% from the prior year.
- Capital Expenditures retreated to $504000.0 in Q1 2026, from $517000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $19.1 million in Q2 2022 to a low of -$20.1 million in Q3 2022.
- A 5-year average of $259882.4 and a median of $206000.0 in 2025 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 179.35% in 2024, while the deepest fall reached 5232.14% in 2024.
- Tracing CRSP's Capital Expenditures over 5 years: stood at -$2.8 million in 2022, then soared by 99.0% to -$28000.0 in 2023, then sank by 5232.14% to -$1.5 million in 2024, then jumped by 134.63% to $517000.0 in 2025, then slipped by 2.51% to $504000.0 in 2026.
- Business Quant data shows CRSP's Capital Expenditures at $504000.0 in Q1 2026, $517000.0 in Q4 2025, and $74000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | 504,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 504,000.00 |
| Mar 31, 2026 | 504,000.00 |
| Dec 31, 2025 | 517,000.00 |
| Dec 31, 2025 | 517,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 117,000.00 |
| Mar 31, 2025 | 206,000.00 |
| Mar 31, 2025 | 206,000.00 |
| Dec 31, 2024 | -1.49 Mn |
| Dec 31, 2024 | -1.49 Mn |
| Sep 30, 2024 | 219,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Jun 30, 2024 | 707,000.00 |
| Jun 30, 2024 | 707,000.00 |
| Mar 31, 2024 | 721,000.00 |
| Mar 31, 2024 | 721,000.00 |
| Dec 31, 2023 | -28,000.00 |
| Dec 31, 2023 | -28,000.00 |